Exicure

Exicure, founded in 2011 and headquartered in Chicago, Illinois, is a clinical-stage biotechnology company specializing in the development of therapeutics using its proprietary spherical nucleic acid (SNA) technology. Its pipeline includes AST-008 for advanced solid tumors, XCUR-FXN for Friedreich’s ataxia, and XCUR17 targeting interleukin 17 receptor alpha. Exicure has collaborations with Allergan Pharmaceuticals International Limited and DERMELIX, LLC.